Al­ler­gan antes up $90M in a land­mark CRISPR/Cas9 col­lab­o­ra­tion with Ed­i­tas on eye dis­eases

Al­ler­gan is jump­ing in­to the CRISPR busi­ness.

The biotech struck a deal to part­ner with CRISPR/Cas9 leader Ed­i­tas $ED­IT on up to five pro­grams aimed at cur­ing eye dis­eases. And the pack­age in­cludes Ed­i­tas’ lead pro­gram for Leber Con­gen­i­tal Amau­ro­sis (LCA10), which is cur­rent­ly wrap­ping pre­clin­i­cal re­search with an eye to mov­ing in­to the clin­ic in pos­si­bly the first hu­man CRISPR study in the US.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN